سعر لاسيداك 4 مجم 14 قرص 2022

Lacidipine 4 mg film-coated tablet, pack of 14 tablets; dihydropyridine calcium channel blocker for hypertension.

• Treatment of hypertension, either alone or in combination with other antihypertensive agents, including beta-adrenoceptor antagonists, diuretics and ACE inhibitors.Population: Adultsemc (medicines.org.uk)

• Common adverse reactions: dizziness, headache, palpitations, tachycardia, flushing, abdominal discomfort, nausea, rash, erythema, pruritus, polyuria, asthenia, oedema and increased blood alkaline phosphatase; vasodilatory effects are usually transient.International label, equivalent formulation · emc (medicines.org.uk)
• Uncommon or rare adverse reactions: syncope, angina pectoris, hypotension, gingival hyperplasia, angioedema, urticaria and muscle cramps; very rarely tremor and depression.International label, equivalent formulation · emc (medicines.org.uk)

• Hypersensitivity to lacidipine or to any of the excipients.International label, equivalent formulation · emc (medicines.org.uk)
• Aortic stenosis (dihydropyridines reduce coronary arterial blood flow in these patients).International label, equivalent formulation · emc (medicines.org.uk)
• Use during or within one month of a myocardial infarction.International label, equivalent formulation · emc (medicines.org.uk)

• Use with caution in patients with pre-existing abnormalities of SA or AV node activity, poor cardiac reserve, or impaired liver function (antihypertensive effect may be increased).International label, equivalent formulation · emc (medicines.org.uk)
• Use with caution in patients with congenital or acquired QT prolongation and with drugs that prolong the QT interval (e.g. class I and III antiarrhythmics, tricyclic antidepressants, some antipsychotics, erythromycin, some antihistamines).International label, equivalent formulation · emc (medicines.org.uk)
• Efficacy and safety in malignant hypertension have not been established, and there is no evidence of benefit in secondary prevention of myocardial infarction.International label, equivalent formulation · emc (medicines.org.uk)

• Other antihypertensive agents (e.g. diuretics, beta-blockers, ACE inhibitors)May have an additive hypotensive effect; no specific interaction problems were identified with common antihypertensives, digoxin, tolbutamide or warfarin.emc (medicines.org.uk)
• CimetidineMay increase plasma levels of lacidipine.emc (medicines.org.uk)
• Grapefruit juiceShould not be taken with lacidipine as bioavailability may be altered.emc (medicines.org.uk)

• Pregnancy: there are no data on the safety of lacidipine in human pregnancy; animal studies showed no teratogenic effect but maternal toxicity at high doses and prolonged, difficult labour due to uterine relaxation. Use only when the potential benefit to the mother outweighs possible adverse effects in the foetus or neonate.International label, equivalent formulation · emc (medicines.org.uk)
• Breast-feeding: animal milk-transfer studies show lacidipine or its metabolites are likely excreted in breast milk; use during breast-feeding only when the potential benefit to the mother outweighs possible adverse effects.International label, equivalent formulation · emc (medicines.org.uk)

• Lacidipine: Specific, potent calcium antagonist with predominant selectivity for calcium channels in vascular smooth muscle; dilates peripheral arterioles, reducing peripheral vascular resistance and blood pressure (UK SmPC section 5.1).